Track: Artificial Intelligence in Cancer Prognosis

The session on Artificial Intelligence in Cancer Prognosis will illustrate how advanced computational tools are moving beyond data analysis to fundamentally transform the entire continuum of cancer care.

A major focus will be on Machine Learning Applications in Digital Pathology. High-resolution digitized tissue slides provide massive amounts of data; AI algorithms can rapidly identify tumor margins, accurately grade malignancies, quantify mitosis rates, and even detect subtle patterns indicative of molecular subtypes, assisting pathologists and reducing diagnostic turnaround time.

This technology extends to medical imaging through Radiomics and Deep Learning for Image Prognosis. Radiomics involves using AI to extract hundreds of quantitative features from standard medical images (CT, MRI, PET) that are often imperceptible to the human eye. These features are then fed into deep learning models to create predictive signatures that can accurately forecast recurrence risk, overall survival, or response to specific therapies, providing a non-invasive prognostic tool.

The session will cover the development of sophisticated Predictive Modeling for Treatment Response and Toxicity. By integrating clinical, genomic, and imaging data, AI models can generate highly individualized risk scores, helping oncologists decide whether to intensify or de-escalate therapy. This efficiency is mirrored in Natural Language Processing (NLP) for EHR Data Extraction, where AI analyzes unstructured clinical notes and reports in Electronic Health Records (EHRs), converting them into structured, usable data for research and quality improvement, accelerating knowledge discovery.

Furthermore, we explore the use of AI in Drug Discovery and Biomarker Identification. AI can rapidly screen massive chemical libraries in silico to identify potential therapeutic molecules, predict drug toxicity, and uncover new combinatorial drug targets by analyzing complex genomic networks.

This directly impacts Clinical Trial Optimization and Patient Matching, where AI accelerates enrollment by precisely identifying eligible patients based on specific genomic profiles and clinical characteristics, thereby reducing trial costs and time.

Finally, a critical discussion on Ethical Frameworks and Regulatory Challenges for Clinical AI ensures that the adoption of these powerful tools maintains data privacy, avoids algorithmic bias, and adheres to stringent regulatory standards for clinical deployment.

4th International Conference on Cancer and Breast Cancer Treatment

Track: Artificial Intelligence in Cancer Prognosis

Scientific Highlights

Organization Location

Mail us at

Our Social Presence

Call us at